Irofulven
- Generic Name
- Irofulven
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C15H18O3
- CAS Number
- 158440-71-2
- Unique Ingredient Identifier
- 6B799IH05A
- Background
A novel anti-cancer compound synthesized by scientists at the University of California, San Diego more than a decade ago from toxins of the poisonous jack-o-lantern mushroom, has been granted โfast trackโ status by the U.S. Food and Drug Administration (FDA) after demonstrating promise against one of the most deadly cancers.
MGI-114 (Irofulven) is currently being developed by MGI PHARMA, Inc., an emerging oncology-focused pharmaceutical company based in Minneapolis. Phase III clinical trials involving the drug have been underway since early 2001 at sites in the U.S. and Europe.
- Indication
Investigated for use/treatment in brain cancer, breast cancer, endometrial cancer, liver cancer, lung cancer, ovarian cancer, pancreatic cancer, pediatric indications, prostate cancer, and sarcoma.
- Associated Conditions
- -
- Associated Therapies
- -
Irofulven in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Peritoneal Cancer
- Conditions
- First Posted Date
- 2004-04-13
- Last Posted Date
- 2013-06-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT00019552
- Locations
- ๐บ๐ธ
Medicine Branch, Bethesda, Maryland, United States
Irofulven in Treating Patients With Persistent or Recurrent, Refractory Endometrial Cancer
- Conditions
- First Posted Date
- 2004-03-31
- Last Posted Date
- 2013-05-27
- Lead Sponsor
- Gynecologic Oncology Group
- Registration Number
- NCT00005031
- Locations
- ๐บ๐ธ
Kimmel Cancer Center of Thomas Jefferson University - Philadelphia, Philadelphia, Pennsylvania, United States
๐บ๐ธUniversity of Pennsylvania Cancer Center, Philadelphia, Pennsylvania, United States
๐บ๐ธFox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Irofulven in Treating Children With Recurrent or Refractory Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2004-02-09
- Last Posted Date
- 2013-02-05
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 12
- Registration Number
- NCT00003370
- Locations
- ๐บ๐ธ
Hackensack University Medical Center, Hackensack, New Jersey, United States
๐บ๐ธChildren's Hospital of Columbus, Columbus, Ohio, United States
๐บ๐ธDana-Farber Cancer Institute, Boston, Massachusetts, United States
Irofulven Compared With Fluorouracil in Treating Patients With Pancreatic Cancer
- First Posted Date
- 2004-01-15
- Last Posted Date
- 2012-12-24
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 158
- Registration Number
- NCT00033735
- Locations
- ๐บ๐ธ
MGI Pharma, Incorporated, Bloomington, Minnesota, United States
Irofulven in Treating Patients With Recurrent or Metastatic Gastric Cancer
- Conditions
- First Posted Date
- 2003-06-06
- Last Posted Date
- 2013-05-15
- Lead Sponsor
- Cancer Therapeutics Research Group
- Registration Number
- NCT00062257
- Locations
- ๐ฐ๐ท
Yonsei Cancer Center at Yonsei University Medical Center, Seoul, Korea, Republic of
๐ฆ๐บSydney Cancer Centre at Royal Prince Alfred Hospital, Sydney, New South Wales, Australia
๐ธ๐ฌJohns Hopkins - Singapore, Singapore, Singapore
Irofulven in Treating Patients With Recurrent or Persistent Ovarian Epithelial or Primary Peritoneal Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-01-28
- Last Posted Date
- 2019-07-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 61
- Registration Number
- NCT00053365
- Locations
- ๐บ๐ธ
Gynecologic Oncology Group, Philadelphia, Pennsylvania, United States
Irofulven in Treating Patients With Metastatic Breast Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-02-11
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 32
- Registration Number
- NCT00003796
- Locations
- ๐บ๐ธ
University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States
Chemotherapy in Treating Patients With Progressive or Recurrent Brain Tumors
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-06-24
- Lead Sponsor
- New Approaches to Brain Tumor Therapy Consortium
- Registration Number
- NCT00012038
- Locations
- ๐บ๐ธ
Emory University Hospital - Atlanta, Atlanta, Georgia, United States
๐บ๐ธMassachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
๐บ๐ธComprehensive Cancer Center at Wake Forest University, Winston-Salem, North Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.